Skip to content
Subscriber Only

CDC Advises Against Using AstraZeneca’s FluMist Next Season


The U.S. Centers for Disease Control and Prevention advised against using AstraZeneca Plc’s FluMist nasal vaccine in the upcoming flu season after a panel found it wasn’t effective enough in the last three influenza seasons.

The CDC’s findings contrasts with AstraZeneca’s own studies about the efficacy of the inhaled product, which garnered sales of $206 million in the U.S. in the last fiscal year, the London-based drugmaker said in a statement.